Holen Sie sich die Stockscreener-App
0.576
4.38%
-0.0264
Schlusskurs vom Vortag:
$0.6024
Offen:
$0.58
24-Stunden-Volumen:
206.72K
Relative Volume:
0.06
Marktkapitalisierung:
$6.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+7.87%
1M Leistung:
+40.49%
6M Leistung:
-98.53%
1J Leistung:
-99.44%
1-Tages-Spanne:
$0.5719
$0.6332
1-Wochen-Bereich:
$0.5496
$0.8481
52-Wochen-Spanne:
$0.375
$269.28
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Vergleichen Sie AEON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.576 | 6.04M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Expands Team with 100K+ Stock Awards: Inside the Biotech's Latest Hiring Move - Stock Titan
Aeon Biopharma Reports Positive Q1 2025 Earnings - TipRanks
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 - The Manila Times
AEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual Conference - Nasdaq
AEON Biopharma Unveils Next-Gen Botulinum Toxin Therapies: CEO Details Multi-Indication Pipeline - Stock Titan
AEON Biopharma Advances Biosimilar Product Development and Appoints New CEO - Nasdaq
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
New AEON CEO Targets $3.3B Botox Market with FDA-Ready Biosimilar Development Plan - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Tuesday - Defense World
Closing Bell Recap: AEON Biopharma Inc (AEON) Ends at 0.75, Reflecting a -11.76 Downturn - DWinneX
AEON Biopharma Inc (AMEX: AEON) Stock: Investors Need To Know This - Stocksregister
Is AEON Biopharma Inc’s (AMEX:AEON) Stock On The Decline? - Stocksregister
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com Australia
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma Inc (AEON) Stock: The Story of a 52-Week Stock Range - investchronicle.com
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
AEON Biopharma Announces CEO Transition - The Manila Times
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Es liegen keine Finanzdaten für AEON Biopharma Inc. (AEON) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
Kapitalisierung:
|
Volumen (24h):